Merrimack Pharmaceuticals Inc.
101 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 617-441-1000
Fax: 617-491-1386
Website: http://www.merrimackpharma.com/
Email: info@merrimackpharma.com
300 articles about Merrimack Pharmaceuticals Inc.
-
Merrimack Pharmaceuticals Inc. Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
10/11/2011
-
FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals Inc.' MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
8/2/2011
-
Merrimack Pharmaceuticals Inc. Files $172.5 Million IPO
7/11/2011
-
Merrimack Pharmaceuticals Inc. Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
6/30/2011
-
PharmaEngine, Inc. and Merrimack Pharmaceuticals Inc. Enter into a Licensing and Collaboration Agreement; PharmaEngine Eligible for $220 Million Upfront and Milestone Payments Plus Royalties
5/9/2011
-
Merrimack Pharmaceuticals Inc. Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
4/20/2011
-
Merrimack Pharmaceuticals Inc. Raises $77 Million
4/14/2011
-
Phase 1 Data on Merrimack Pharmaceuticals Inc.'s MM-121 Will Be Presented at the 102nd Annual Meeting of the American Association for Cancer Research
4/5/2011
-
Merrimack Pharmaceuticals Inc. Announces the Addition of Michael Porter to its Board of Directors
1/25/2011
-
Merrimack Pharmaceuticals Inc. Awarded $2.44 Million in Grants Under the Patient Protection and Affordable Care Program
11/9/2010
-
Merrimack Pharmaceuticals Inc. to Present at the 2010 Stifel Nicolaus Healthcare Conference
9/13/2010
-
Merrimack Pharmaceuticals Inc. and Sanofi-Aventis (France) Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer
7/22/2010
-
Merrimack Pharmaceuticals Inc.'s MM-111 Phase 1/2 Trial Design to be Presented at the 2010 American Society of Clinical Oncology Annual Meeting
6/3/2010
-
Merrimack Pharmaceuticals Inc. to Present at the Jefferies 2010 Global Life Sciences Conference
6/2/2010
-
Merrimack Pharmaceuticals Inc. to Present at Biotechnology Industry Organization (BIO) on the Development of MM-111, a Novel Bispecific ErbB2/ErbB3 Antibody with Potent Anti-Tumor Activity
5/3/2010
-
Merrimack Pharmaceuticals Inc. to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of the American Association for Cancer Research
4/19/2010
-
Merrimack Pharmaceuticals Inc. Initiates Enrollment in a Phase 1/2 Combination Study of MM-121 and Tarceva(R) in Patients with Non-Small Cell Lung Cancer
2/22/2010
-
Sanofi-Aventis (France) and Merrimack Pharmaceuticals Inc. Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121; Merrimack Eligible to Receive up to $530 Million
10/1/2009
-
GTC Biotherapeutics in-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals Inc.
7/8/2009
-
Merrimack Pharmaceuticals Inc. Presents Pre-Clinical Data on MM-121 and MM-111 at the Annual Meeting of the American Association for Cancer Research
4/17/2009